Insulin degludec 

Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes^[1][2].

IC50: 19.59 nM/L (insulin receptor)^[2]

Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC₅₀ value of 19.59 nM^[2].
Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

844439-96-9

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture and light, under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

• [1]. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.  [Content Brief]

  [2]. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul  [Content Brief]